Organ systems

OM1 Launches Multiple Sclerosis Registry with More than 20,000 Patients Prospectively Followed with Deep Clinical Data

Retrieved on: 
Wednesday, July 14, 2021
Multiple sclerosis, Medical specialties, Neurology, Organ systems, Clinical medicine, Expanded Disability Status Scale, OM1, EDSS, Autoimmune diseases

BOSTON, July 14, 2021 /PRNewswire/ -- OM1 , a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry .

Key Points: 
  • BOSTON, July 14, 2021 /PRNewswire/ -- OM1 , a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry .
  • Registry provides access to MS patients longitudinal outcomes, EDSS scores, relapses, subtypes, and treatment response.
  • The OM1 MS registry is a continually updating database of more than 20,000 patients prospectively followed with deep clinical, laboratory and other data, such as longitudinal outcomes, Expanded Disability Status Scale (EDSS) scores, relapses, subtypes, and treatment response.Additionally, researchers can tap into data from another 460,000 MS patients in the OM1 Real-World Data Cloud,which can be used for modelling, analytics, and other research purposes.
  • "Early diagnosis and effective treatment are the best way to reduce the damaging effects and to improve an MS patient's quality of life."

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Organ systems, Medical specialties, Hepatology, Uremic pruritus, Cholestasis, Itch, Antipruritics, Nalfurafine, EP547 for Cholestatic and Uremic Pruritus, Escient Pharmaceuticals, EP547 FOR CHOLESTATIC AND UREMIC PRURITUS, ESCIENT PHARMACEUTICALS

The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.

Key Points: 
  • The study found that EP547 was safe and well-tolerated in both healthy volunteers and patients with chronic cholestatic or kidney disease at all doses tested.
  • EP547 was found to be safe and well-tolerated with no serious adverse events, no adverse events leading to discontinuation, and no safety signals identified.
  • By blocking these pruritogens from activating MrgprX4, Escient believes EP547 has the potential to effectively treat both cholestatic and uremic pruritus.
  • Drug development to address cholestatic and uremic pruritus has been hampered by the lack of basic biological understanding of the relevant mechanisms.

Global Diabetic Nephropathy Epidemiology and Patient Flow Report 2021: Prevalence, Diagnosed, and Drug-treated Patients to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Diabetes, Diabetes, Kidney diseases, Medical specialties, Organ systems, Clinical medicine, Diabetic nephropathy

The "Global Diabetic Nephropathy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Diabetic Nephropathy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Diabetic Nephropathy Epidemiology and Patient Flow Analysis - 2021, provides Diabetic Nephropathy epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Diabetic Nephropathy patients, history of the disease at the population level (Diabetic Nephropathy prevalence, Diabetic Nephropathy incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Diabetic Nephropathy patients by age group, gender
    The data from this research will help executives:
    Establish basis for Diabetic Nephropathy market sizing, assessing market potential, and developing drug forecast models
    Identify Diabetic Nephropathy patients segments through age groups, gender, and disease sub-types
    Evaluate Diabetic Nephropathy market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005464/en/

Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne

Retrieved on: 
Wednesday, July 14, 2021
Organ systems, Organs anatomy), Hair diseases, Human hair, Acneiform eruptions, Testosterone, Acne, Pattern hair loss, Hair loss, Cioteronel

Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "Kintor started to build up PROTAC platform in 2018, based on which Kintor developed AR-PROTAC (GT20029), an innovative topical drug.

Key Points: 
  • Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "Kintor started to build up PROTAC platform in 2018, based on which Kintor developed AR-PROTAC (GT20029), an innovative topical drug.
  • Both indications of androgenetic alopecia and acne have huge unmet clinical needs, and we hope to accelerate the clinical progress to provide safe and effective treatments for people who suffer from androgenetic alopecia and acne."
  • The excessive activation of systemic and local androgen receptor pathways is an important link in the pathogenesis of androgenetic alopecia and acne.
  • Among the causes of acne are genetics, stress, high humidity, use of oily or greasy personal care products and fluctuating hormone levels.

Nonprofit to Award $50,000 to Pulmonary Hypertension Research at Annual Virtual Town Hall

Retrieved on: 
Tuesday, July 13, 2021
Hypertension, Pulmonary hypertension, Beloit, Anatomy, Branches of biology, Organ systems

BELOIT, Wis., July 13, 2021 /PRNewswire-PRWeb/ -- Nonprofit Team PHenomenal Hope (Team PH) will announce the 2021 winner of the PHenomenal Impact Fund for Global PH Research Award at its second annual Virtual Town Hall titled, "Living With Pulmonary Hypertension Beyond the Pandemic" on Saturday, July 17 at noon ET.

Key Points: 
  • BELOIT, Wis., July 13, 2021 /PRNewswire-PRWeb/ -- Nonprofit Team PHenomenal Hope (Team PH) will announce the 2021 winner of the PHenomenal Impact Fund for Global PH Research Award at its second annual Virtual Town Hall titled, "Living With Pulmonary Hypertension Beyond the Pandemic" on Saturday, July 17 at noon ET.
  • In this virtual town hall clinical experts, pulmonary hypertension (PH) patients, nurses, and doctors will discuss relevant patient-centered topics, as well as recent research findings.
  • Paula Menezes, 2020 research award recipient, will also share her findings in the work supported by the 2020 award.
  • Team PH founder and president Patricia George shares, "This is a day to celebrate pulmonary hypertension research with Team PHenomenal Hope!

Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve

Retrieved on: 
Tuesday, July 13, 2021
Rare diseases, Branches of biology, Organ systems, Musculoskeletal disorders, Channelopathies, Electrolyte disturbances, Nephrology, Potassium, Hypokalemic periodic paralysis, Periodic paralysis, Hyperkalemic periodic paralysis, Diclofenamide

The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.

Key Points: 
  • The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.
  • Collectively, these results reinforce the utility of KEVEYIS as an effective option in treating PPP, a life-long rare, hereditary skeletal muscle disorder that leads to debilitating attacks of muscle weakness.
  • KEVEYIS (dichlorphenamide) is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • The companys rare neuromuscular franchise includes KEVEYIS (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.

US Type 1 Diabetes Market and Competitive Landscape 2021: Phase 3, Phase 2, and Phase 1 by Pharmacological Class and Companies Developing the Products - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Health, Diabetes, Diabetes, Organ systems, Health, Clinical medicine, Type 1 diabetes

The "US Type 1 Diabetes Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Type 1 Diabetes Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Type 1 Diabetes Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Type 1 Diabetes pipeline products, Type 1 Diabetes epidemiology, Type 1 Diabetes market valuations and forecast, Type 1 Diabetes drugs sales and competitive landscape in the US.
  • Type 1 Diabetes pipeline: Find out the products in clinical trials for the treatment of Type 1 Diabetes by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Type 1 Diabetes drugs: Identify key products marketed and prescribed for Type 1 Diabetes in the US, including trade name, molecule name, and company
    Type 1 Diabetes drugs sales: Find out the sales revenues of Type 1 Diabetes drugs in the US
    Type 1 Diabetes market valuations: Find out the market size for Type 1 Diabetes drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Type 1 Diabetes drugs market share: Find out the market shares for key Type 1 Diabetes drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Type 1 Diabetes products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005525/en/

Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Pharmaceutical, Health, Clinical trials, Medical devices, Idiopathic pulmonary fibrosis, Lung disorders, Boehringer Ingelheim, Pulmonary fibrosis, IPF, Health, Orphan drugs, Organ systems, Monoclonal antibodies, Pneumonia, Fresolimumab

The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I.
  • Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, closely followed by Boehringer Ingelheim.

Panasonic Releases New Trimmer Designed for First-Time Shavers

Retrieved on: 
Monday, July 12, 2021
Organ systems, Anatomy, Tools, Facial hair, Shaving, Acneiform eruptions, Acne, Hair removal, Facial, Panasonic, Trimmer, String trimmer

NEWARK, N.J., July 12, 2021 /PRNewswire/ -- Today, Panasonic released the Panasonic Wet/Dry Facial Hair Remover (ER-GM40-K), a trimmer specifically designed for a younger generation who are beginning to grow facial hair and whose skin is prone to irritation.

Key Points: 
  • NEWARK, N.J., July 12, 2021 /PRNewswire/ -- Today, Panasonic released the Panasonic Wet/Dry Facial Hair Remover (ER-GM40-K), a trimmer specifically designed for a younger generation who are beginning to grow facial hair and whose skin is prone to irritation.
  • Safety, skin sensitivity and acne breakouts, and hesitancy to use their dads' shavers are a few concerns we heard from teenagers about shaving.
  • Already awarded the iF Gold Design Award 2021 earlier this year for its exceptional product design, the Panasonic Wet/Dry Facial Hair Remover (ER-GM40-K) is the first in a new category of trimmer for Panasonic.
  • Connect with Panasonic Corporation of North America:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/panasonic-releases-new-trimmer-...

Allena Pharmaceuticals Provides Update on Clinical Development Programs

Retrieved on: 
Monday, July 12, 2021
Nitrogen cycle, Triketones, Uric acid, Branches of biology, Inborn errors of purine-pyrimidine metabolism, Kidney, Organ systems, Anatomy, Acute uric acid nephropathy, Hyperuricemia

Evaluation of clinical and laboratory parameters revealed no significant safety signals and no serious adverse events were reported.

Key Points: 
  • Evaluation of clinical and laboratory parameters revealed no significant safety signals and no serious adverse events were reported.
  • Key bioactivity endpoints will include serum uric acid level, 24-hour urine uric acid level, and renal clearance of uric acid.
  • Allena Pharmaceuticals, Inc.is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.
  • All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.